Genicular Artery Embolisation (GAE) for Knee Arthritis
Genicular artery embolisation is the newest of the treatments offered to delay a knee replacement. What the procedure involves, what the trials have and have not shown, what it costs in Australia, and the questions to ask before paying for it.
Genicular artery embolisation — GAE — is the newest thing being offered to people who want to delay a knee replacement, and the one patients are most likely to have encountered without their GP mentioning it.
It deserves a more careful treatment than either of the two positions it usually attracts: the clinic promising a knee replacement avoided, and the blanket dismissal of anything unfamiliar.
What it actually is
An interventional radiology procedure, not an operation. No incision, no implant, nothing removed.
Under local anaesthetic and light sedation, a fine catheter is introduced into an artery at the wrist or in the groin and steered under X-ray guidance to the genicular arteries — the small vessels supplying the lining of the knee. Microscopic particles are then injected to reduce the blood flow through the abnormal part of that supply.
It takes an hour or two, it is a day procedure, and most people are back to ordinary activity within a few days.
The reasoning behind it
Reasonable, which is what makes it interesting.
In an arthritic knee the synovium — the lining of the joint — becomes inflamed and thickened. Inflamed synovium grows an abnormal network of new blood vessels, and new nerve fibres grow alongside them. Those nerve fibres are part of why an arthritic knee hurts, and why the pain does not track neatly with how worn the X-ray looks.
Reduce the abnormal blood supply, the argument goes, and you reduce the inflamed tissue and the nerve supply that came with it — and so the pain.
That is a coherent mechanism aimed at a real feature of arthritis, which is more than can be said for several of the things sold to people with sore knees.
What the trials show
Here is where care is needed.
The early studies were encouraging. Series of patients treated and followed for six months to two years reported substantial pain reduction in a majority, with benefit persisting in many.
Single-arm studies overstate benefit for knee pain specifically. This is not a criticism of the researchers; it is a well-established property of the knee. Almost any procedure performed on a painful knee produces improvement in a group of patients, including procedures later shown to do nothing. It is why the gel injection story unfolded the way it did.
Sham-controlled trials are the test that matters, and for GAE they remain small, few in number and mixed in their results. Some have found a benefit over a sham procedure; others have found the difference smaller than the single-arm work suggested.
The Australian guideline does not address it. The RACGP guideline for knee and hip osteoarthritis predates GAE’s arrival in ordinary practice. This is a genuinely different situation from gel injections and stem cell therapy, which the guideline assessed and recommended against. Not yet assessed is not the same as recommended against — and it is not the same as recommended, either.
The fair summary: plausible mechanism, promising early signal, evidence not yet settled, longer-term data still accumulating. It is the most interesting of the newer options and the least resolved.
Who it is aimed at
From the studies published so far, the patients most likely to benefit have:
- Mild to moderate arthritis, rather than a bone-on-bone knee with significant deformity
- An inflammatory pattern — a knee that swells, feels warm, is tender to touch and hurts at rest and at night
- Failed the things that work — genuine attempts at exercise, weight management and sensible medication, rather than token ones
- A reason not to have surgery yet — age, medical unfitness, work or family commitments, or simply not being ready
The group it has been studied in least is the group most likely to ask about it: people whose arthritis has reached the point where a replacement is clearly the operation that would help.
The risks
Mostly minor, and worth knowing:
- Bruising or discomfort at the wrist or groin access site
- Patchy skin discolouration or numbness over the knee, where particles reach small skin vessels. Usually temporary
- A flare of knee pain in the days afterwards
- Small areas of skin breakdown, less commonly
- Rarely, bone damage from loss of blood supply to a small area
- Radiation exposure, and an iodinated contrast agent — relevant if your kidney function is impaired
The honest caveat that applies to all of them: complications that emerge over five or ten years cannot yet be counted, because not enough people have been followed that long.
What it costs
Generally not covered by Medicare for knee osteoarthritis, and health fund coverage is limited and variable. Most patients pay out of pocket, and the figure is usually several thousand dollars once the procedure, the imaging, the facility fee and the sedation are included.
Ask for the total, in writing, before agreeing. Ask specifically whether follow-up imaging, a repeat procedure or treatment of the other knee is included, because those are the items that commonly are not.
What to ask before paying
The same three questions that apply to any knee treatment you are paying for yourself, plus one specific to this:
- What benefit should I expect, and for how long?
- What do the sham-controlled trials show, as distinct from the single-arm studies?
- Am I the kind of patient this has been studied in — and if not, what does that change?
- What would you suggest instead, and why is this better for my knee specifically?
A clinician who engages with the second question is giving you a straight answer. Reluctance on it is informative.
Where this leaves you
GAE is not the same category as the things this site recommends against. It has a real mechanism, an accumulating evidence base and a plausible place in the treatment of knee arthritis. It may well turn out to have one.
It is also not a knee replacement avoided, it does not repair anything, and the case for it is not yet made. If you are considering it, the sensible position is: know that you are paying for a treatment whose evidence is still being assembled, know which group you fall into, and be clear about what would count as it having worked.
And if your knee has already reached the point where the arthritis is advanced, the pain dominates your day and the things that work have genuinely been tried, then the more useful conversation is probably about whether it is time rather than about another procedure first.
Next: Tablets, creams and supplements — or back to the overview.
What is genicular artery embolisation?+
A procedure performed by an interventional radiologist rather than a surgeon, in which a fine catheter is threaded through an artery at the wrist or groin to the small arteries supplying the lining of the knee, and microscopic particles are injected to reduce the blood flow to inflamed tissue. The reasoning is that an arthritic knee lining grows an abnormal network of new blood vessels, that new nerve fibres accompany them, and that reducing this abnormal supply reduces pain. It does not touch cartilage or bone, and it does not replace anything.
Does GAE work for knee arthritis?+
The early single-arm studies were encouraging, with many patients reporting meaningful pain reduction lasting months to a couple of years. The difficulty is that knee pain responds strongly to any procedure, so single-arm results tend to overstate benefit. The trials that compare GAE against a sham procedure — the design that separates real effect from expectation — remain small and their results mixed. The fair summary is that it is plausible, actively researched and not yet settled, which is a genuinely different position from the treatments the Australian guideline recommends against.
Is genicular artery embolisation available in Australia, and is it covered by Medicare?+
It is available in Australia through interventional radiology services in the major cities, including Perth. For knee osteoarthritis it is generally not covered by Medicare, and health fund coverage is limited and variable, so most patients pay out of pocket — commonly several thousand dollars once the procedure, imaging, facility and sedation fees are counted. Ask for the total figure in writing before committing, and ask specifically what is and is not included.
Who is GAE most likely to suit?+
The patients described as doing best are those with mild to moderate arthritis whose pain has an inflammatory character — a knee that is swollen, warm and tender, with pain at rest and at night — rather than end-stage arthritis with bone rubbing on bone and significant deformity. It is also raised for people who cannot have surgery for medical reasons, or who have a reason to postpone it. A knee that is already at the point where a replacement is clearly indicated is not the situation in which it has been most studied.
What are the risks of genicular artery embolisation?+
The commonly reported problems are minor and temporary: bruising or discomfort at the access site, transient patches of skin discolouration or numbness over the knee where particles reach skin vessels, and a short flare of knee pain afterwards. Less common are small areas of skin breakdown and, rarely, damage to bone from loss of blood supply. There is also radiation exposure and a contrast agent, which matter if kidney function is impaired. As with any newer procedure, the long-term picture is less complete than the short-term one.
Does GAE regrow cartilage or stop arthritis progressing?+
No. It is a treatment aimed at pain, not at the disease. It does not restore cartilage, it does not correct deformity, and there is no evidence that it alters the course of the arthritis. Anyone presenting it as regenerative or as a way of reversing arthritis is describing something the procedure does not do.
Will having GAE make a knee replacement harder later?+
There is no good evidence that it does, and there is not yet enough long-term data to state it confidently either way — which is an honest answer rather than an evasive one. It is a reasonable question to put to whoever is offering the procedure, and to raise with your surgeon if a replacement is likely to be on the horizon within a few years.